Keyphrases
Melanoma
98%
T Cells
91%
Cancer Immunotherapy
88%
Adoptive Cell Therapy
84%
Tumor-infiltrating Lymphocytes
84%
Recent Advances
63%
Tumor Killing
61%
CD4+
56%
IFN Signaling
52%
Immune Escape
49%
Cancer Therapy
46%
Beta-blockers
42%
Adrenergic Receptors
42%
Adrenergic Receptor Signaling
42%
JAK Signaling
42%
Pancreatic Cancer
42%
Phase II Study
42%
Ipilimumab
42%
Tocilizumab
42%
Stereotactic Body Radiotherapy
42%
Adrenergic Signaling
42%
Cancer Immunity
42%
Nivolumab
42%
Antigen-specific T Cells
42%
Acquired Resistance
42%
Proteomics
42%
Mass Spectrometry Analysis
42%
MHC Class I Antigen Presentation
42%
Anti-PD-1 Immunotherapy
42%
Anti-programmed Death 1
42%
Tumor Cells
40%
Clinical Trials
35%
β2-microglobulin (β2-MG)
33%
Confidence Interval
31%
Tumor
30%
Janus Kinase 1 (JAK1)
28%
Immune Checkpoint Blockade
26%
Drug-resistant Tumor
26%
Cancer Types
25%
Therapeutic Efficacy
25%
Immune Resistance
24%
Cancer Cells
21%
Clinical Value
21%
In Cancer
21%
Progressive Disease
21%
Cancer Incidence
21%
Physical Activity
21%
Lifestyle Modification
21%
Natural Killer Cells
21%
Cancer Mechanisms
21%
Medicine and Dentistry
Immunotherapy
100%
Tumor Infiltrating Lymphocyte
98%
Nodular Melanoma
88%
Neoplasm
68%
Adrenergic Receptor
42%
Antigen Presentation
42%
Cell Therapy
42%
Tocilizumab
42%
Nivolumab
42%
Ipilimumab
42%
Pancreas Cancer
42%
Stereotactic Body Radiation Therapy
42%
Malignant Neoplasm
42%
T Cell
38%
Beta 2 Microglobulin
28%
Janus Kinase 1
28%
Immune Checkpoint Blockade
26%
Cancer Therapy
25%
Clinical Trial
24%
Immunity
24%
Cell Mediated Cytotoxicity
21%
Progressive Disease
21%
Tumor Cell
19%
Infusion
15%
Specific Tumor
15%
Tumor Microenvironment
14%
Combination Therapy
14%
Tumor Progression
14%
Lymphocyte Activation
14%
CD8 Antigen
14%
Interleukin 6
10%
T-Helper Cell
10%
Secretion (Process)
10%
Cancer Cell
10%
Signal Transduction
10%
Lifestyle Modification
10%
Cancer Model
10%
Adverse Event
10%
Natural Killer Cell
10%
Receptor
10%
Disease
10%
Physical Activity
10%
Cells of the Immune System
10%
Progression Free Survival
10%
Epinephrine
10%
Overall Survival
10%
Lifespan
10%
Gemcitabine
10%
Fluorouracil
10%
T-Cell Response
5%
Immunology and Microbiology
Immunotherapy
71%
T Cell
70%
CD4
56%
Tumor-Infiltrating Lymphocytes
56%
Antigen Specificity
42%
Tumor Immunity
42%
MHC Class I
42%
Antigen Presentation
42%
Immune Escape
42%
Nivolumab
42%
T Cell Receptor
42%
Tocilizumab
42%
Ipilimumab
42%
Tumor Cell
32%
Beta-2 Microglobulin
28%
Cancer Immunotherapy
28%
Immunity
24%
Immune Checkpoint Blockade
23%
Cytotoxicity
18%
Immunocompetent Cell
14%
Cancer Survival
14%
Protein Protein Interaction
14%
Antigen Recognition
14%
Protein Processing
14%
Signal Transduction
14%
CD8
14%
Lymphocyte Activation
14%
Cell Function
14%
Progression Free Survival
10%
Overall Survival
10%
Interleukin 6
10%
Cytokine
9%
Major Histocompatibility Complex
9%
MHC Class II
9%
T-Helper Cell
9%
Cytotoxic T-Cell
6%